EBV tetramers with HLA restriction
| Tetramer . | EBV epitope . | Epitope AA sequence . |
|---|---|---|
| A2-GLC-lytic | BMLF1 280-288 | GLCTLVAML |
| A2-LLD-latent | EBNA3C 284-293 | LLDFVRFMGV |
| A2-CLG-latent | LMP2 426-434 | CLGGLLTMV |
| B7-RPP-latent | EBNA3A 379-387 | RPPIFIRRL |
| B7-VPA-latent | EBNA3A 502-510 | VPAPAGPIV |
| B8-RAK-lytic | BZLF1 190-197 | RAKFKQLL |
| B8-QAK-latent | EBNA3A 158-166 | QAKWRLQTL |
| B8-FLR-latent | EBNA3A 325-333 | FLRGRAYGL |
| Tetramer . | EBV epitope . | Epitope AA sequence . |
|---|---|---|
| A2-GLC-lytic | BMLF1 280-288 | GLCTLVAML |
| A2-LLD-latent | EBNA3C 284-293 | LLDFVRFMGV |
| A2-CLG-latent | LMP2 426-434 | CLGGLLTMV |
| B7-RPP-latent | EBNA3A 379-387 | RPPIFIRRL |
| B7-VPA-latent | EBNA3A 502-510 | VPAPAGPIV |
| B8-RAK-lytic | BZLF1 190-197 | RAKFKQLL |
| B8-QAK-latent | EBNA3A 158-166 | QAKWRLQTL |
| B8-FLR-latent | EBNA3A 325-333 | FLRGRAYGL |